Eloralintide

Eloralintide
Clinical data
Other names	LY3841136
Identifiers
CAS Number	2883634-40-8;
PubChem SID	497621299;
UNII	73G3354J8W;
KEGG	D12886;
Chemical and physical data
Formula	C201H319N49O65S2
Molar mass	4526.16 g·mol−1

Eloralintide (LY3841136) is an experimental drug that works as a selective amylin receptor agonist. It was designed to activate the amylin receptor without off-target effects at the calcitonin receptor. In one human study, those receiving the highest dose lost 20 percent of their body weight.^[1]^[2]

References

↑ Billings, Liana K.; Hsia, Stanley; Bays, Harold; Tidemann-Miller, Beth; O’Hagan, Jessica; Tham, Lai San; Butler, Annabelle; Kazda, Christof; Mather, Kieren J.; Coskun, Tamer (6 December 2025). "Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial". The Lancet. 406 (10520): 2631–2643. doi:10.1016/S0140-6736(25)02155-5. ISSN 0140-6736.
↑ Tatananni, Mackenzie. "Lilly's Next Obesity Drug Could Be the Real Catalyst for the Stock". barrons. Retrieved 7 August 2026.

[1] Billings, Liana K.; Hsia, Stanley; Bays, Harold; Tidemann-Miller, Beth; O’Hagan, Jessica; Tham, Lai San; Butler, Annabelle; Kazda, Christof; Mather, Kieren J.; Coskun, Tamer (6 December 2025). "Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial". The Lancet. 406 (10520): 2631–2643. doi:10.1016/S0140-6736(25)02155-5. ISSN 0140-6736.

[2] Tatananni, Mackenzie. "Lilly's Next Obesity Drug Could Be the Real Catalyst for the Stock". barrons. Retrieved 7 August 2026.

[1]

[2]